Interview with Dr. Adam M Hill, CEO, Oncimmune plc
Hear from Dr. Adam M Hill, Chief Executive Officer, Oncimmune plc discuss the business, the market opportunity and why investors should be excited about Oncimmune.
About Oncimmune plc
Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Oncimmune has a diversified and growing revenue from its portfolio of diagnostic products to detect early-stage cancer and a contract discovery and development service-based platform, delivering actionable insights into therapies to its pharmaceutical and biotech partners.
Oncimmune’s ImmunoINSIGHTS platform enables life-science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients. Oncimmune’s immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. The lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, it is poised to become an integral component of future lung cancer detection programmes, globally.
Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a partner representative office in Shanghai, China.
Further information is available at oncimmune.com
Singer Capital Markets is acting as Joint Broker to Oncimmune plc.